Sionna Therapeutics, Inc.
NASDAQ:SIONBiotechnology
+$0.68 today
- Market cap
- $134.35M
- Beta
- 1.29
- P/E (TTM)
- -19.7
- EPS (TTM)
- -$1.90
Volume 0.52M
Average 0.39M
SION Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Sionna Therapeutics, Inc.NASDAQ: SION
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities rises 52.7% from a year ago
Other current liabilities stood at $1.51M at the end of Q1 FY2026, up 52.7% from a year earlier and down 68.2% from the prior quarter. Over 3 fiscal years it compounded at +34.4% a year.
Context
- Other current liabilities amounted to 0.5% of total assets at the end of Q1 FY2026, up 0.2 pp from a year earlier.
- Other current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other current liabilities keeps rising in the next quarterly balance sheet after a +52.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 4.75M USD
- Year-over-year change
- +59.7%
- 3-year CAGR
- +34.4%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.75M | +59.7% |
| FY2024 | 2024-12-31 | 2.97M | -4.5% |
| FY2023 | 2023-12-31 | 3.11M | +59.3% |
| FY2022 | 2022-12-31 | 1.95M | — |
Other Current Liabilities vs competitors
How SION compares with its peers on the latest reported figures
- SION's Mar 2026 other current liabilities of $1.51M is the 8th highest of the 11 companies compared; the peer median is $6.82M.
- Its year-over-year change of +52.7% is the 3rd highest of 10, against a peer median of +21.4%.
- Other current liabilities amounts to 0.5% of total assets for SION, versus a peer median of 1.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $100.86M | +211.5% | +54.4% | 25.7% | |
| Jun 2026 | $45.88M | +20.5% | +59.7% | 12.4% | |
| Sep 2026 | $40.97M | +359.6% | +97.7% | 8.1% | |
| Mar 2026 | $9.38M | +30.9% | +87.7% | 1.9% | |
| Sep 2026 | $8.22M | — | — | 0.5% | |
| Mar 2026 | $5.42M | -25.5% | +13.2% | 1.3% | |
| Mar 2026 | $2.25M | +21.4% | +33.3% | 0.2% | |
| Mar 2026 | $1.51M | +52.7% | +34.4% | 0.5% | |
| Sep 2026 | $1.23M | +32.3% | +7.5% | 0.2% | |
| Jun 2026 | $0 | -100.0% | — | 0.0% | |
| Sep 2026 | -$11.93M | -141.7% | -15.5% | 1.0% | |
| Peer median (excluding SION) | $6.82M | +21.4% | +43.9% | 1.2% | |
Competitors are the stored peer set for SION. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Sionna Therapeutics, Inc.
NASDAQ:SION
Intrinsic Alpha fair value
Locked
Current Price
$2.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.